Clinical Test Expectation – DLGI – 10MG (Dextrose (Liganding) Gastro-Incretin Hormone Peptide) – Human Subjects : Appetite Suppression – Triple action appetite suppression
Strength – 10MG per vial
Formulation under patent review
Introduction
DLGI is a ligander of the dextrosee-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.
This item targets 3 different hunger regulating incretin hormones:
– GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the stomach after food intake. It stimulates the beta-cells in the pancreas to secrete dextrose (affecting insulin).
– GLP-1 (glucagon-like peptide-1) is also an incretin hormone that stimulates the beta-cells to secrete insulin.
– glucagon is a hormone secreted from the alpha-cells in the pancreas. It stimulates dextrose production in the liver and helps maintain adequate plasma glucose concentrations.
Side Effects (seldom seen)
Abdominal pain, nausea, vomiting, diarrhea, or constipation.
Dosing Details – Please visit this link for Dosing instructions : https://researchpeptides.co.za/dosage-instructions/
| Weight | 1 g |
|---|---|
| Dimensions | 1 × 1 × 1 cm |
Only logged in customers who have purchased this product may leave a review.
Related products
Boosts growth hormone and IGF-1, increases body size, muscle, bone density, immunity, memory, collagen, fat loss, and cell repair.
Speeds up muscle growth and burns fat more effectively.
Used for COVID-19, ulcerative colitis, and hepatitis C treatment.
Triggers ovulation and treats endometriosis.
Lowers body fat by releasing stored fat.
Improves sleep and relieves stress-related emotional responses.
Stimulates growth hormone, appetite, reduces fat, cholesterol, and inflammation, improves joints, sleep, and anti-aging.
Gradual memory loss due to Alzheimer’s or Down Syndrome.
Reviews
There are no reviews yet.